P0X Stock Overview
A clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pharnext S.C.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.01 |
| 52 Week High | €70,000,000.00 |
| 52 Week Low | €0.01 |
| Beta | -306.33 |
| 1 Month Change | -90.43% |
| 3 Month Change | -98.98% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| P0X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -60.2% | 0.4% | 0.6% |
| 1Y | -100.0% | -23.7% | 5.4% |
Return vs Industry: P0X underperformed the German Biotechs industry which returned -23.7% over the past year.
Return vs Market: P0X underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| P0X volatility | |
|---|---|
| P0X Average Weekly Movement | 46.9% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: P0X's share price has been volatile over the past 3 months.
Volatility Over Time: P0X's weekly volatility has decreased from 468% to 47% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Hugo Brugiere | pharnext.com |
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Pharnext S.C.A. Fundamentals Summary
| P0X fundamental statistics | |
|---|---|
| Market cap | €11.41k |
| Earnings (TTM) | -€31.55m |
| Revenue (TTM) | €1.82m |
0.0x
P/S Ratio0.0x
P/E RatioIs P0X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P0X income statement (TTM) | |
|---|---|
| Revenue | €1.82m |
| Cost of Revenue | €0 |
| Gross Profit | €1.82m |
| Other Expenses | €33.37m |
| Earnings | -€31.55m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -181.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,733.56% |
| Debt/Equity Ratio | -79.0% |
How did P0X perform over the long term?
See historical performance and comparison